SANTARUS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-12-13: Form 8-K; Period of report 2010-12-10; Description 8.01 Other Events; Details 8.01.
- 2010-11-19: Form 8-K; Period of report 2010-11-17; Description 3.02 Unregistered Sales of Equity Securities; Details 3.02.
- 2010-11-08: Form 8-K; Period of report 2010-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2010-11-08: Form 8-K; Period of report 2010-11-08; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-12-13 | 8-K | 2010-12-10 | 8.01 Other Events | 8.01 On December 8, 2010, a complaint styled as a putative class action was filed against Santarus, Inc. (the “Company”) in the United States District Court for the Southern District of New York by a person employed by the Company as a sales representative and on behalf of a class of similarly situated current and former employees of the Company. | a58121e8vk.htm |
| 2010-11-19 | 8-K | 2010-11-17 | 3.02 Unregistered Sales of Equity Securities | 3.02 Pursuant to the license agreement, stock issuance agreement and registration rights agreement between Santarus, Inc. (the “Company”) and Cosmo Technologies Limited (“Cosmo”) entered into in December 2008, Cosmo earned a $3.0 million clinical milestone in November 2010 based upon the positive results of the U.S. and European Phase III clinical studies for budesonide MMX®. | a57911e8vk.htm |
| 2010-11-08 | 8-K | 2010-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2010, Santarus, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2010. | a57778e8vk.htm |
| 2010-11-08 | 8-K | 2010-11-08 | 8.01 Other Events | 8.01 On November 8, 2010, Santarus, Inc. (“Santarus” or the “Company”) issued a press release announcing positive top-line results from the Phase III clinical study conducted in Europe to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. | a57776e8vk.htm |
| 2010-09-29 | 8-K | 2010-09-29 | 8.01 Other Events | 8.01 On September 29, 2010, Santarus, Inc. (“Santarus” or the “Company”) issued a press release announcing positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. | a57415e8vk.htm |
| 2010-09-21 | 8-K | 2010-09-20 | 8.01 Other Events | 8.01 Santarus, Inc. (“Santarus”) disclosed on September 20, 2010 that Schering-Plough HealthCare Products, Inc., a subsidiary of Merck & Co., Inc. (“Schering-Plough”), has filed lawsuits on September 20, 2010 in the United States District Court for the District of New Jersey against each of Par Pharmaceutical, Inc. (“Par”) and Perrigo Research and Development Company (“Perrigo”) for infringement of the patents listed in the Orange Book for Zegerid OTC® (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules). | a57370e8vk.htm |
| 2010-09-14 | 8-K | 2010-09-13 | 7.01 Regulation FD Disclosure | 7.01 On September 13, 2010 at 6:00 a.m. | a57296e8vk.htm |
| 2010-09-13 | 8-K | 2010-09-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a57279e8vk.htm |
| 2010-09-13 | 8-K | 2010-09-10 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. | a57278e8vk.htm |
| 2010-09-09 | 8-K | 2010-09-08 | 7.01 Regulation FD Disclosure | 7.01 On September 8, 2010 at 2:00 p.m. | a57248e8vk.htm |
| 2010-09-08 | 8-K | 2010-09-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a57237e8vk.htm |
| 2010-09-03 | 8-K/A | 2010-09-01 | 2.05 Costs Associated with Exit or Disposal Activities | 2.05 At the time of the Original 8-K filing, the Company was unable in good faith to make an estimate of the non-cash charges related to the Company’s offer to accelerate the vesting of stock options and extend the period for exercising vested stock options for affected employees. | a57219e8vkza.htm |
| 2010-08-30 | 8-K | 2010-08-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a57167e8vk.htm |
| 2010-08-20 | 8-K | 2010-08-20 | 8.01 Other Events | 8.01 Santarus, Inc. (“Santarus” or the “Company”) is disclosing that Depomed, Inc. (“Depomed”) has provided an update on the status of its activities related to the resupply of Glumetza® (metformin hydrochloride extended release) 500 mg tablets. | a57135e8vk.htm |
| 2010-08-11 | 8-K | 2010-08-10 | 8.01 Other Events | 8.01 Santarus, Inc. (“Santarus”) disclosed on August 10, 2010 that Schering-Plough HealthCare Products, Inc., a subsidiary of Merck & Co., Inc. (“Schering-Plough”), has received a Notice of Paragraph IV Certification from Par Pharmaceutical, Inc. (“Par”) advising of the submission of an Abbreviated New Drug Application (“ANDA”) for an over-the-counter (“OTC”) version of omeprazole and sodium bicarbonate capsules, 20 mg/1100 mg. | a56988e8vk.htm |
| 2010-08-02 | 8-K | 2010-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2010, Santarus, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2010. | a56892e8vk.htm |
| 2010-06-30 | 8-K | 2010-06-30 | 1.01 Entry into a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.05 On June 30, 2010, in connection with the Company’s decision to cease promotion of Zegerid® (omeprazole/sodium bicarbonate) prescription products effective immediately, the Board of Directors of Santarus determined to implement a corporate restructuring, including a workforce reduction of approximately 37%, or approximately 120 employees, in its commercial organization and certain other operations. 8.01 On June 30, 2010, Santarus announced that pursuant to its previously-disclosed distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription Zegerid® (omeprazole/sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. | a56615e8vk.htm |
| 2010-06-17 | 8-K | 2010-06-17 | 8.01 Other Events | 8.01 Santarus, Inc. (“Santarus” or the “Company”) is disclosing that Depomed, Inc. (“Depomed”) is conducting a voluntary recall from wholesalers of 52 lots of Glumetza® 500mg (metformin hydrochloride extended release) tablets due to the presence of trace amounts of a chemical called 2,4,6-tribromoanisole (TBA) in bottles containing 500mg Glumetza tablets. | a56529e8vk.htm |
| 2010-06-14 | 8-K | 2010-06-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2010 annual meeting of stockholders of Santarus, Inc. (the “Company”) was held on June 10, 2010. | a56495e8vk.htm |
| 2010-05-28 | 8-K | 2010-05-28 | 8.01 Other Events | 8.01 As part of its contingency plan to prepare for a possible launch of a generic version of its Zegerid® (omeprazole/sodium bicarbonate) prescription products, Santarus has entered into a Distribution and Supply Agreement (the “Distribution Agreement”), dated April 26, 2010, with Prasco, LLC (“Prasco”), which grants Prasco the right to distribute and sell an authorized generic version of Santarus’ Zegerid prescription products in the United States. | a56349e8vk.htm |
| 2010-05-14 | 8-K | 2010-05-14 | 8.01 Other Events | 8.01 On May 14, 2010, Santarus, Inc. (the “Company”) filed an appeal of the U.S. District Court for the District of Delaware’s ruling that five patents covering Zegerid® Capsules and Zegerid® Powder for Oral Suspension (U.S. Patent Nos. 6,489,346; 6,645,988; 6,699,885; 6,780,882; and 7,399,772) are invalid due to obviousness to the U.S. Court of Appeals for the Federal Circuit. | a55953e8vk.htm |
| 2010-05-06 | 8-K | 2010-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2010, Santarus, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2010. | a56041e8vk.htm |
| 2010-04-15 | 8-K | 2010-04-14 | 8.01 Other Events | 8.01 On April 14, 2010, Santarus, Inc. (“Santarus”) announced that the U.S. District Court for the District of Delaware has ruled that five patents covering Santarus’ Zegerid® (omeprazole/sodium bicarbonate) prescription products are invalid due to obviousness. | a55823e8vk.htm |
| 2010-03-03 | 8-K | 2010-03-03 | 2.02 Results of Operations and Financial Condition | 2.02 On March 3, 2010, Santarus, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2009. | a55368e8vk.htm |
| 2010-02-19 | 8-K | 2010-02-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 At a meeting held on February 18, 2010, the independent members of the Board of Directors of Santarus, Inc. (the “Company”), based on a recommendation by the Compensation Committee, approved the Santarus, Inc. 2010 Bonus Plan (the “2010 Bonus Plan”). | a55273e8vk.htm |
| 2010-02-02 | 8-K | 2010-02-01 | 8.01 Other Events | 8.01 Santarus, Inc. (“Santarus” or the “Company”) participated in a telephone conference on February 1, 2010 with Chief Judge Gregory M. Sleet of the United States District Court for the District of Delaware and other parties. | a55017e8vk.htm |
| 2010-01-15 | 8-K | 2010-01-15 | 8.01 Other Events | 8.01 On January 15, 2010, Santarus, Inc. (“Santarus” or the “Company”) filed with the United States District Court for the District of Delaware a motion for preliminary injunction. | a54874e8vk.htm |